🇺🇸 FDA
Patent

US 11661401

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors

granted A61PA61P35/02A61P35/04

Quick answer

US patent 11661401 (2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors) held by Revolution Medicines, Inc. expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Revolution Medicines, Inc.
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P35/02, A61P35/04